Screening of New Compounds
Non-clinical and pre-clinical work often requires making critical decisions on which compounds to keep and which to discard. Depending on stage of R&D and company finances, there are differential costs for 'false positives' (concluding a compound to be effective, when it is not) and 'false negatives.' Working together with your scientists, TechnoSTAT will design decision-making algorithms that will enable you to determine study designs and sample sizes that optimize the likelihood of identifying your company's most promising compounds.